Developer docs
API playgroundTry for free, no card

Search company profiles

MH3D

Full company profile

uuid0003i4p

Namestring
MH3D
Legal namestring
MH3D Inc.
Websiteurl
mh3dinc.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

MH3D Inc. is a privately held medical device company founded in 2023 and headquartered in Ann Arbor, Michigan, that develops next-generation preclinical SPECT (Single-Photon Emission Computed Tomography) imaging systems for nuclear medicine research. Its flagship and sole commercial product is the Alpha-SPECT™ Mini, the world's first CZT (Cadmium Zinc Telluride) semiconductor detector-based preclinical SPECT system. The platform delivers approximately 2.5% energy resolution at 140 keV, a fully stationary detector geometry with a dual-FOV micro-scanning aperture, multi-isotope imaging (including direct imaging of alpha-emitting radiopharmaceuticals such as Actinium-225), and supports up to four mice per scan for biodistribution, dosimetry, PK/PD, and longitudinal theranostics studies. Underlying IP traces to over two decades of nuclear imaging detector research at the University of Michigan (Dr. Zhong He, 3D-readout technique) and the University of Illinois at Urbana-Champaign (Dr. Ling-Jian Meng), with commercialization led by CEO Xiaopei Huang.

MH3D monetizes the Alpha-SPECT Mini primarily through capital equipment sales of high-priced preclinical imaging systems to contract research organizations (CROs) and academic medical centers. Go-to-market combines direct enterprise field sales, a distribution partnership with Scintica Instrumentation, and event-driven demand generation at WMIC, SNMMI, and the Preclinical Imaging Consortium. The company sells through quote-based enterprise pricing with multi-year contract terms, supplemented by an exclusive service partnership with Perceptive Discovery that launched the α-Sight™ imaging service in April 2026, converting MH3D's installed hardware into a recurring outsourced imaging offering for pharma/biotech sponsors. Customers disclosed to date are Johns Hopkins University School of Medicine, Perceptive Discovery, and Minerva Imaging (Europe). The firm had 1–10 employees as of latest disclosure and closed a single funding round of approximately $3.31M in January 2025.

Short descriptiontext

MH3D Inc. is a medical device company that builds and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system for direct in vivo imaging of alpha-emitting radiopharmaceuticals, sold primarily to contract research organizations and academic medical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCommerce Township, United States
HQ citystring
Commerce Township
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical SPECT imaging, CZT semiconductor detectors, nuclear imaging systems, radiopharmaceutical imaging devices, molecular imaging instrumentation
Industry3 codes
PRIMARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Preclinical Nuclear Imaging Systems
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Alpha-SPECT Mini Hardware Sales
TypeHardware Sales
Description

Sale of Alpha-SPECT Mini CZT-based preclinical SPECT imaging systems to CROs, academic institutions, and research organizations. Each unit represents a significant capital sale with potential for follow-on service contracts.

mh3dinc.com
2Service Partnership Revenue
TypeManaged Services
Description

Perceptive Discovery serves as MH3D's exclusive service provider, offering α-Sight imaging services. This creates recurring service revenue through the partnership model while MH3D supplies the hardware platform.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Alpha-SPECT Mini System - quote-based enterprise pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. Direct sales engagement required for quotes on preclinical SPECT imaging system.

mh3dinc.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Alpha-SPECT Mini
Description

World's first CZT-based preclinical SPECT imaging system for alpha-emitting radiopharmaceuticals with unmatched energy resolution and sensitivity.

mh3dinc.com
+1 more record
Core offering1 text field

MH3D designs, develops, and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system used by contract research organizations and academic medical centers for direct in vivo imaging and quantification of alpha-emitting radiopharmaceuticals in cancer, cardiovascular, and neurodegenerative disease research. The company also enables the α-Sight imaging service via an exclusive service-provider partnership with Perceptive Discovery, and offers an integrated SPECT/CT solution through a partnership with Inviscan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • High quantification accuracy (~1–10% error across multiple energy peaks)
+3 more records
Product overview1 text field

MH3D is a medical device company with a single flagship product: the Alpha-SPECT™ Mini, the world's first CZT-based preclinical SPECT imaging system. The product targets early detection and monitoring of cancer, cardiovascular, and neurodegenerative diseases by enabling direct in vivo imaging of alpha-emitting radiopharmaceuticals. MH3D's commercial strategy includes selling the Alpha-SPECT™ Mini system directly to research institutions and CROs (e.g., Johns Hopkins, Perceptive Discovery, Minerva Imaging), with Perceptive Discovery operating as the exclusive service provider using the system for the α-Sight™ imaging service offering. The system is also offered as an integrated SPECT/CT solution via a partnership with Inviscan's IRIS CT system.

Product and service1 record
1Alpha-SPECT Mini
CategoryPreclinical SPECT Imaging Systems
Description

World's first CZT-based preclinical SPECT imaging system designed for high-sensitivity, high-resolution imaging of alpha-emitting radiopharmaceuticals. Offers dual-field-of-view (standard and focused modes), multi-isotope imaging capability, ~2.5% energy resolution at 140 keV, and sub-2.5 mm spatial resolution. Used by contract research organizations and academic medical centers for biodistribution studies, dosimetry modeling, PK/PD assessment, tumor targeting validation, and longitudinal imaging of theranostic agents in cancer, cardiovascular, and neurodegenerative disease research.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-04-20
Description

Minerva Imaging purchased Alpha-SPECT Mini unit, marking first adoption of MH3D's technology in Europe. Minerva Imaging is a globally recognized CRO specializing in radiopharmaceutical imaging and translational research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Strategic partnership where Perceptive Discovery serves as MH3D's exclusive service provider. The partnership launched α-Sight, a preclinical imaging service for alpha-emitting radiopharmaceuticals using the Alpha-SPECT Mini. Perceptive Discovery provides radiochemistry, imaging, and quantitative image analysis expertise to expand isotope portfolio and decision-making outputs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Strategic partnership where Inviscan provides the high-performance IRIS CT system for the SPECT/CT integrated solution offered at Johns Hopkins. The CT modality enables attenuation correction and precise anatomical registration of SPECT images, supporting perfusion imaging, cardiac and pulmonary gating, and vascular imaging applications.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Scintica Instrumentation serves as a distribution partner for the Alpha-SPECT Mini system, extending MH3D's market reach in the preclinical imaging instrumentation space.

5UK Science and Technology Facilities Council (STFC)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

UK research council that has provided support for MH3D's development of cutting-edge imaging technology for preclinical and clinical research communities.

mh3dinc.com
Strategic tierSupportingTypeTechnology or Integration
Description

Technology partner supporting MH3D's development and launch of the Alpha-SPECT Mini imaging platform.

Strategic tierSupportingTypeTechnology or Integration
Description

Partner supporting MH3D's mission to bring cutting-edge imaging technology to preclinical and clinical research communities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bruker's BioSpin preclinical imaging division sells high-field MRI, PET, SPECT, and CT systems to research institutions and CROs, directly competing with MH3D's Alpha-SPECT Mini for the same preclinical imaging budgets.

TypeDirect peer
Description

MILabs manufactures preclinical SPECT, PET, and optical imaging systems (e.g., VECTor, U-SPECT) used in radiopharmaceutical and molecular imaging research — overlapping directly with MH3D's preclinical SPECT value proposition.

TypeDirect peer
Description

Mediso sells preclinical nanoSPECT/CT and PET/SPECT/CT systems to academic and CRO preclinical imaging labs, competing head-to-head for nuclear-medicine small-animal imaging capital purchases.

TypeBroad incumbent
Description

Revvity offers a broad portfolio of preclinical imaging instruments, radiopharmaceutical reagents, and CRO services, overlapping with MH3D's customer base (CROs and academic researchers) and product category (preclinical imaging).

TypeBroad incumbent
Description

GE HealthCare is a global leader in clinical and preclinical nuclear medicine imaging (SPECT, SPECT/CT, PET), targeting the same radiopharmaceutical and theranostics research customers as MH3D at much larger scale.

TypeBroad incumbent
Description

Siemens Healthineers provides clinical and research SPECT/PET systems and CZT-based digital detectors in its broader imaging portfolio, anchoring the incumbent landscape that MH3D must differentiate against.

TypeDirect peer
Description

Trifoil Imaging supplies preclinical Inveon PET/SPECT/CT and optical imaging platforms to translational imaging labs, directly comparable to MH3D's preclinical nuclear imaging offering.

TypeDirect peer
Description

Spectral Instruments Imaging builds preclinical optical and gamma cameras/SPECT systems used in small-animal molecular imaging research, overlapping with MH3D's preclinical imaging customer base.

TypeEmerging player
Description

Inviscan produces high-performance preclinical CT systems (IRIS CT) and is already a technology integration partner of MH3D for SPECT/CT solutions at Johns Hopkins — adjacent preclinical imaging player with overlapping accounts.

TypeOthers
Description

Scintica is MH3D's distribution partner for the Alpha-SPECT Mini and also distributes competing preclinical imaging modalities (ultrasound, MRI, optical), giving it a portfolio view of the same buyer base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MH3D

Preclinical Nuclear Imaging Systemsmh3dinc.com

MH3D Inc. is a medical device company that builds and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system for direct in vivo imaging of alpha-emitting radiopharmaceuticals, sold primarily to contract research organizations and academic medical centers.

What MH3D does

MH3D Inc. is a privately held medical device company founded in 2023 and headquartered in Ann Arbor, Michigan, that develops next-generation preclinical SPECT (Single-Photon Emission Computed Tomography) imaging systems for nuclear medicine research. Its flagship and sole commercial product is the Alpha-SPECT™ Mini, the world's first CZT (Cadmium Zinc Telluride) semiconductor detector-based preclinical SPECT system. The platform delivers approximately 2.5% energy resolution at 140 keV, a fully stationary detector geometry with a dual-FOV micro-scanning aperture, multi-isotope imaging (including direct imaging of alpha-emitting radiopharmaceuticals such as Actinium-225), and supports up to four mice per scan for biodistribution, dosimetry, PK/PD, and longitudinal theranostics studies. Underlying IP traces to over two decades of nuclear imaging detector research at the University of Michigan (Dr. Zhong He, 3D-readout technique) and the University of Illinois at Urbana-Champaign (Dr. Ling-Jian Meng), with commercialization led by CEO Xiaopei Huang.

MH3D monetizes the Alpha-SPECT Mini primarily through capital equipment sales of high-priced preclinical imaging systems to contract research organizations (CROs) and academic medical centers. Go-to-market combines direct enterprise field sales, a distribution partnership with Scintica Instrumentation, and event-driven demand generation at WMIC, SNMMI, and the Preclinical Imaging Consortium. The company sells through quote-based enterprise pricing with multi-year contract terms, supplemented by an exclusive service partnership with Perceptive Discovery that launched the α-Sight™ imaging service in April 2026, converting MH3D's installed hardware into a recurring outsourced imaging offering for pharma/biotech sponsors. Customers disclosed to date are Johns Hopkins University School of Medicine, Perceptive Discovery, and Minerva Imaging (Europe). The firm had 1–10 employees as of latest disclosure and closed a single funding round of approximately $3.31M in January 2025.

MH3D firmographics

Firmographics
Name
MH3D
Legal name
MH3D Inc.
Website
https://mh3dinc.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
MH3D Inc. is a medical device company that builds and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system for direct in vivo imaging of alpha-emitting radiopharmaceuticals, sold primarily to contract research organizations and academic medical centers.
Ownership category
akta.pro rank

MH3D industry classification

Industry
Product category
Preclinical Nuclear Imaging Systems
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Preclinical SPECT imaging
  • CZT semiconductor detectors
  • Nuclear imaging systems
  • Radiopharmaceutical imaging devices
  • Molecular imaging instrumentation

Where MH3D is headquartered

Location

Headquarters

HQ city
Commerce Township
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MH3D business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Alpha-SPECT Mini Hardware Sales: Sale of Alpha-SPECT Mini CZT-based preclinical SPECT imaging systems to CROs, academic institutions, and research organizations. Each unit represents a significant capital sale with potential for follow-on service contracts.
  2. Service Partnership Revenue: Perceptive Discovery serves as MH3D's exclusive service provider, offering α-Sight imaging services. This creates recurring service revenue through the partnership model while MH3D supplies the hardware platform.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractAlpha-SPECT Mini System - quote-based enterprise pricing

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

MH3D product offering

Product offering

Core offering

MH3D designs, develops, and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system used by contract research organizations and academic medical centers for direct in vivo imaging and quantification of alpha-emitting radiopharmaceuticals in cancer, cardiovascular, and neurodegenerative disease research. The company also enables the α-Sight imaging service via an exclusive service-provider partnership with Perceptive Discovery, and offers an integrated SPECT/CT solution through a partnership with Inviscan.

Product overview

MH3D is a medical device company with a single flagship product: the Alpha-SPECT™ Mini, the world's first CZT-based preclinical SPECT imaging system. The product targets early detection and monitoring of cancer, cardiovascular, and neurodegenerative diseases by enabling direct in vivo imaging of alpha-emitting radiopharmaceuticals. MH3D's commercial strategy includes selling the Alpha-SPECT™ Mini system directly to research institutions and CROs (e.g., Johns Hopkins, Perceptive Discovery, Minerva Imaging), with Perceptive Discovery operating as the exclusive service provider using the system for the α-Sight™ imaging service offering. The system is also offered as an integrated SPECT/CT solution via a partnership with Inviscan's IRIS CT system.

Differentiator

Problem solved

Functional benefit

Brands

  • Alpha-SPECT Mini: World's first CZT-based preclinical SPECT imaging system for alpha-emitting radiopharmaceuticals with unmatched energy resolution and sensitivity.
  • α-Sight

Products and services

  • Alpha-SPECT Mini World's first CZT-based preclinical SPECT imaging system designed for high-sensitivity, high-resolution imaging of alpha-emitting radiopharmaceuticals. Offers dual-field-of-view (standard and focused modes), multi-isotope imaging capability, ~2.5% energy resolution at 140 keV, and sub-2.5 mm spatial resolution. Used by contract research organizations and academic medical centers for biodistribution studies, dosimetry modeling, PK/PD assessment, tumor targeting validation, and longitudinal imaging of theranostic agents in cancer, cardiovascular, and neurodegenerative disease research.

Quantifiable outcome

  • High quantification accuracy (~1–10% error across multiple energy peaks)
  • +3 more outcomes

Companies that use MH3D

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

MH3D technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

MH3D partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major, core and supporting.

  • Minerva ImagingmajorTechnology or Integration · 20 April 2026Minerva Imaging purchased Alpha-SPECT Mini unit, marking first adoption of MH3D's technology in Europe. Minerva Imaging is a globally recognized CRO specializing in radiopharmaceutical imaging and translational research.
  • Perceptive DiscoverycoreStrategic or Co-development Partner · 15 April 2026Strategic partnership where Perceptive Discovery serves as MH3D's exclusive service provider. The partnership launched α-Sight, a preclinical imaging service for alpha-emitting radiopharmaceuticals using the Alpha-SPECT Mini. Perceptive Discovery provides radiochemistry, imaging, and quantitative image analysis expertise to expand isotope portfolio and decision-making outputs.
  • InviscancoreStrategic or Co-development Partner · 1 November 2025Strategic partnership where Inviscan provides the high-performance IRIS CT system for the SPECT/CT integrated solution offered at Johns Hopkins. The CT modality enables attenuation correction and precise anatomical registration of SPECT images, supporting perfusion imaging, cardiac and pulmonary gating, and vascular imaging applications.
  • Scintica InstrumentationmajorChannel Partner/ Reseller/ DistributorScintica Instrumentation serves as a distribution partner for the Alpha-SPECT Mini system, extending MH3D's market reach in the preclinical imaging instrumentation space.
  • UK Science and Technology Facilities Council (STFC)supportingStrategic or Co-development PartnerUK research council that has provided support for MH3D's development of cutting-edge imaging technology for preclinical and clinical research communities.
  • Aspect Systems GmbHsupportingTechnology or IntegrationTechnology partner supporting MH3D's development and launch of the Alpha-SPECT Mini imaging platform.
  • GeofabricasupportingTechnology or IntegrationPartner supporting MH3D's mission to bring cutting-edge imaging technology to preclinical and clinical research communities.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

MH3D competitors and assessment

Company assessment

Direct peers

  • Bruker: Bruker's BioSpin preclinical imaging division sells high-field MRI, PET, SPECT, and CT systems to research institutions and CROs, directly competing with MH3D's Alpha-SPECT Mini for the same preclinical imaging budgets.
  • MILabs: MILabs manufactures preclinical SPECT, PET, and optical imaging systems (e.g., VECTor, U-SPECT) used in radiopharmaceutical and molecular imaging research — overlapping directly with MH3D's preclinical SPECT value proposition.
  • Mediso Medical Imaging Systems: Mediso sells preclinical nanoSPECT/CT and PET/SPECT/CT systems to academic and CRO preclinical imaging labs, competing head-to-head for nuclear-medicine small-animal imaging capital purchases.
  • Trifoil Imaging: Trifoil Imaging supplies preclinical Inveon PET/SPECT/CT and optical imaging platforms to translational imaging labs, directly comparable to MH3D's preclinical nuclear imaging offering.
  • Spectral Instruments Imaging: Spectral Instruments Imaging builds preclinical optical and gamma cameras/SPECT systems used in small-animal molecular imaging research, overlapping with MH3D's preclinical imaging customer base.

Broad incumbents

  • Revvity (formerly PerkinElmer Life Sciences): Revvity offers a broad portfolio of preclinical imaging instruments, radiopharmaceutical reagents, and CRO services, overlapping with MH3D's customer base (CROs and academic researchers) and product category (preclinical imaging).
  • GE HealthCare: GE HealthCare is a global leader in clinical and preclinical nuclear medicine imaging (SPECT, SPECT/CT, PET), targeting the same radiopharmaceutical and theranostics research customers as MH3D at much larger scale.
  • Siemens Healthineers: Siemens Healthineers provides clinical and research SPECT/PET systems and CZT-based digital detectors in its broader imaging portfolio, anchoring the incumbent landscape that MH3D must differentiate against.

Emerging players

  • Inviscan: Inviscan produces high-performance preclinical CT systems (IRIS CT) and is already a technology integration partner of MH3D for SPECT/CT solutions at Johns Hopkins — adjacent preclinical imaging player with overlapping accounts.

Others

  • Scintica Instrumentation: Scintica is MH3D's distribution partner for the Alpha-SPECT Mini and also distributes competing preclinical imaging modalities (ultrasound, MRI, optical), giving it a portfolio view of the same buyer base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

MH3D social profiles

Digital presence

MH3D financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MH3D leadership team

Management profile

Number of profiles

Profiles6 records

MH3D funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MH3D M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MH3D

What does MH3D do?

MH3D designs, develops, and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system used by contract research organizations and academic medical centers for direct in vivo imaging and quantification of alpha-emitting radiopharmaceuticals in cancer, cardiovascular, and neurodegenerative disease research. The company also enables the α-Sight imaging service via an exclusive service-provider partnership with Perceptive Discovery, and offers an integrated SPECT/CT solution through a partnership with Inviscan.

Is MH3D a public or private company?

MH3D is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MH3D founded?

MH3D was founded in 2023. It employs 1 to 10 people.

Where is MH3D based?

MH3D is headquartered in Commerce Township, United States, in the North America region.

How does MH3D make money?

Two revenue lines are on record. Alpha-SPECT Mini Hardware Sales are the primary driver. The others are service Partnership Revenue.

Who are MH3D's main competitors?

Direct peers on record are Bruker, MILabs, Mediso Medical Imaging Systems, Trifoil Imaging and Spectral Instruments Imaging. Broad incumbents are Revvity (formerly PerkinElmer Life Sciences), GE HealthCare and Siemens Healthineers. Inviscan is listed as an emerging player. Scintica Instrumentation is listed as an others.

Does MH3D have an API?

No public API is recorded for MH3D.

What industry is MH3D in?

MH3D's product category is Preclinical Nuclear Imaging Systems. Its primary akta.pro industry code is HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334510 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournPerceptive Discovery Announces Strategic Partnership with MH3D and Launch of α-Sight™ to Advance Alpha Radiopharmaceutical ImagingPerceptive Discovery announced a strategic partnership with MH3D and the launch of α-Sight™, a preclinical imaging offering for direct in vivo visualization of alpha-emitting radiopharmaceuticals. The offering combines MH3D's Alpha-SPECT™ Mini platform with Perceptive Discovery's expertise in imaging, radiochemistry, and quantitative analysis, with Perceptive Discovery serving as MH3D's exclusive service provider. The partnership aims to accelerate candidate selection and de-risk radioligand therapy development programs by enabling high-sensitivity, quantitative whole-body imaging for therapies such as Actinium-225 and Astatine-211.PR NewswirePerceptive Discovery Announces Strategic Partnership with MH3D and Launch of α-Sight™ to Advance Alpha Radiopharmaceutical ImagingPerceptive Discovery announced a strategic partnership with MH3D and launched α-Sight™, a preclinical imaging service enabling direct in vivo visualization of alpha-emitting radiopharmaceuticals. The offering integrates MH3D’s Alpha-SPECT™ Mini CZT-based detection platform with Perceptive Discovery’s preclinical imaging, radiochemistry, and quantitative image analysis expertise, with Perceptive Discovery serving as MH3D’s exclusive service provider. α-Sight™ supports biodistribution studies, tumor targeting validation, and PK/PD assessment to help accelerate radioligand therapy development programs.